CClinicalTrials.gg
Not yet recruitingNCT07849985Updated Sep 30, 2026

Anhedonia Beyond Depressive Symptoms in Children and Adolescents With Conduct Disorder

An observational study in Conduct Disorder and Depression, sponsored by Assiut University. Not yet recruiting. Open to participants aged 12 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Conduct Disorder (CD) is a common psychiatric disorder among children and adolescents and is characterized by a persistent pattern of behaviors that violate the rights of others or major age-appropriate social norms and rules. Although CD is traditionally classified as an externalizing disorder, evidence suggests that some affected adolescents also show abnormalities in emotional and motivational processing, particularly in reward and punishment responsiveness. Anhedonia, defined as reduced ability to experience pleasure, is traditionally considered a core symptom of depression but is increasingly recognized as a transdiagnostic construct that may reflect disturbances in reward processing. Importantly, altered reward responsiveness is not synonymous with clinical anhedonia, and clinically measured anhedonia in adolescents with CD remains insufficiently characterized. Depressive symptoms may contribute to anhedonia and therefore require assessment and statistical control. ADHD is also frequently comorbid with CD and may independently influence reward processing and motivation. Callous-Unemotional traits may additionally overlap with emotional blunting. Therefore, the present study will compare anhedonia in adolescents with CD with or without comorbid ADHD, and healthy controls, while accounting for depressive symptoms and relevant clinical covariates.

02

Conditions studied

  • Conduct Disorder
  • Depression
03

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants aged 12-17 years will be recruited consecutively from the outpatient child and adolescent psychiatry service. Participants meeting criteria for Conduct Disorder will form the clinical group. Healthy controls of comparable age, sex, and socioeconomic status will be recruited from community or school settings. ADHD comorbidity will be assessed within the Conduct Disorder group

Inclusion criteria

  • Age 12-17 years.

    • CD groups: meeting DSM-5 criteria for Conduct Disorder confirmed using the Arabic K-SADS-PL-C DSM-5.
    • Control group: no current or previous psychiatric diagnosis according to the Arabic K-SADS-PL-C DSM-5.
    • Ability to understand and complete the assessment procedures.
    • Written informed consent from a parent/legal guardian and written assent from the adolescent.

Exclusion criteria

Exclusion Criteria:

    • Intellectual disability or severe cognitive impairment interfering with reliable assessment.

      • Autism spectrum disorder or severe neurodevelopmental disorder interfering with self-report.
      • Current psychotic disorder.
      • Current or past bipolar I disorder or manic episode.
      • Current major depressive episode meeting full diagnostic criteria.
      • Current severe substance use disorder.
      • Known neurological disorder, including epilepsy or severe traumatic brain injury.
      • Major uncontrolled medical condition likely to substantially affect mood or hedonic functioning.
      • Current medication expected to substantially affect reward processing or anhedonia, where clinically relevant.
      • Acute suicidal risk or psychiatric condition requiring immediate crisis intervention/hospitalization.
      • Refusal to participate or inability to complete the assessment. Stable stimulant treatment for ADHD may be permitted when clinically necessary and will be recorded as a covariate.
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • cases group

    Participants meeting criteria for Conduct Disorder

  • control group

    healthy control

05

What researchers measure

Primary outcomes

  1. SHAPS total score

    SHAPS total score, representing overall anhedonia severity

    Time frame: baseline

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07849985
Lead sponsor
Assiut University
Responsible party
Katreen Maher (residant doctor at Assiut university hospital, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion